Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Flagella

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Journal of Medicinal Chemistry|May 20, 2015
Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1Lewis Gazzard, Karen Williams, Huifen Chen, et al.
Science Translational Medicine|February 6, 2015
Effect of selective LRRK2 kinase inhibition on nonhuman primate lungReina N Fuji, Michael Flagella, Miriam Baca, et al.
Journal of Medicinal Chemistry|December 21, 2013
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Bryan K Chan, Charles Baker-Glenn, et al.
Journal of Medicinal Chemistry|September 19, 2012
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Xingrong Liu, Charles Baker-Glenn, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Journal of Medicinal Chemistry|August 11, 2012
Potent and highly selective benzimidazole inhibitors of PI3-kinase deltaJeremy M Murray, Zachary K Sweeney, Bryan K Chan, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Journal of Medicinal Chemistry|May 20, 2015
Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1Lewis Gazzard, Karen Williams, Huifen Chen, et al.
Science Translational Medicine|February 6, 2015
Effect of selective LRRK2 kinase inhibition on nonhuman primate lungReina N Fuji, Michael Flagella, Miriam Baca, et al.
Journal of Medicinal Chemistry|December 21, 2013
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Bryan K Chan, Charles Baker-Glenn, et al.
Journal of Medicinal Chemistry|September 19, 2012
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Xingrong Liu, Charles Baker-Glenn, et al.
Pageof 2